201. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates
- Author
-
Sang Joon Kim, Chung Gyu Park, Jung Sik Kim, Hyoung-Soo Cho, Il Hee Yoon, Jong Hyung Lim, Jun Seop Shin, Jae Il Lee, Su Young Kim, Jin-Young Shin, and Ki-Hyun Kim
- Subjects
Graft Rejection ,Male ,Regulatory T cell ,Cell Survival ,Swine ,T-Lymphocytes ,Drug Resistance ,Biology ,Lymphocyte Activation ,T-Lymphocytes, Regulatory ,Bortezomib ,Interleukin 21 ,Immune system ,medicine ,Cytotoxic T cell ,Animals ,Protease Inhibitors ,IL-2 receptor ,Cell Proliferation ,Sirolimus ,Transplantation ,CD28 ,Boronic Acids ,Macaca mulatta ,Disease Models, Animal ,medicine.anatomical_structure ,Pyrazines ,Immunology ,Cancer research ,Swine, Miniature ,Pancreas Transplantation ,Memory T cell ,Immunologic Memory ,Immunosuppressive Agents ,medicine.drug - Abstract
Background. Memory T cells specific for donor antigens are currently recognized as a significant barrier for maintaining a successful transplant. Furthermore, it has been shown that commonly used immunosuppressive drugs do not alleviate this memory response. Here, we report that rapamycin allows significant proliferation of memory T cells and bortezomib can abrogate the proliferation of rapamycin-resistant memory T cells when preserving the survival of regulatory T cells. Methods. Peripheral blood mononuclear cells freshly isolated from non-human primates were stimulated with anti-CD3/ CD28 antibodies, and inhibitory and apoptotic effects of rapamycin and bortezomib on memory T-cell proliferation were investigated. The CD95 marker in CD3T cells was used for the separate enrichment of memory T cells and naive T cells. Results. Rapamycin at the level even higher than therapeutic concentration could not suppress the proliferation of a significant proportion of memory T cells. However, the combined administration of bortezomib and rapamycin abrogatedtheproliferationofrapamycin-resistantmemoryTcells.Furthermore,bortezomibpreservedthesurvivalof preexisting CD4FoxP3 regulatory T cells, while inducing apoptosis of CD4FoxP3 conventional T cells. The combined administration of low doses of rapamycin and bortezomib also exerted an additive effect on suppressing T-cell proliferation. Cytokine analysis demonstrated that bortezomib could not only suppress rapamycin-permissive interleukin (IL)-6 production, but also production of interferon (IFN)-, IL-4, and IL-10. Conclusions. This article provides in vitro data from which immunosuppressive regimens for the effective control of memory T cells in non-human preclinical experiments and in clinical trials are selected.
- Published
- 2009